Avanir appoints William Sibold chief commercial officer

14 Apr 2011

• By Zoë Dann

Avanir Pharmaceuticals has named William Sibold senior vice-president and chief commercial officer. He has more than 20 years' experience in the biopharmaceutical industry, having served as senior vice-president, US commercial, at Biogen Idec, where he was responsible for commercial activities across the neurology, oncology and rheumatology US businesses. Mr Sibold, who has also worked at Lilly and Amgen, was most recently president and CEO of Lycera.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.